Facility Variation in Utilization of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes Mellitus and Chronic Kidney DiseaseByAnjali Tiwari, MBBS, MS,Chin-Lin Tseng, DrPH,Elizabeth F. O. Kern, MD,Miriam Maney, MA, CHPQ,Donald R. Miller, ScD,Leonard Pogach, MD, MBAFebruary 1st 2007
